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Abstract Increased expression of critical components of the 
ubiquitin-dependent proteolytic pathway occurs in any muscle 
wasting condition so far studied in rodents where proteolysis 
rises. We have recently reported similar adaptations in head 
trauma patients [Mansoor et al. (1996) Proc. Natl. Acad. Sci. 
USA 93, 2714-2718l. We demonstrate here that the increased 
muscle protein breakdown seen in mdx mice only correlated with 
enhanced expression of m-calpain, a CaZ+-activated proteinase. 
By contrast, no change in mRNA levels for components of the 
ubiquitin-proteasome proteolytic process was seen in muscles 
from both mdx mice and Duchenne muscular dystrophy patients. 
Thus, gene expression of components of this pathway is not 
regulated in the chronic wasting that characterizes muscular 
dystrophy. 
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1. Introduction 
Duchenne muscular dystrophy (DMD) is the most common 
sex-linked lethal disease in man, affecting approximately 1 in 
3500 boys and resulting in a fatal evolution before the end of 
the third decade of life [1]. This disease is characterized by the 
lack of detectable dystrophin, a very large (400 kDa) cytoskel- 
etal protein [2,3]. In DMD patients and in mdx mice, the 
animal model that reproduces DMD, there is a severe muscle 
wasting. This wasting results from enhanced proteolysis in 
mdx mice [4,5]. 
Like all mammalian tissues, skeletal muscle contains multi- 
ple proteolytic systems. The best known system is the lysoso- 
mal pathway, which involves four major proteinases in muscle 
(cathepsins B, H, L and D). Increased specific activities of 
cathepsin B [6 8], H [8], L [7,8], and D [6] have been reported 
in dystrophic skeletal muscle. However, these increased activ- 
ities of cathepsins were related to the infiltration of non-mus- 
cle cells in both dystrophic hamsters [7] and mdx mice [8], 
although some cathepsin L was co-localized in muscle cells 
as well as in invading macrophages [8]. Skeletal muscle also 
contains two major cytosolic proteolytic pathways, Ca 2+-de- 
pendent [9] and ATP-ubiquitin-dependent [10], respectively. 
Turner et al. [4] showed that the elevation of the concentra- 
tion of intracellular Ca 2+ in muscle fibers from young mdx 
mice resulted in an enhanced protein breakdown. Further- 
more, MacLennan et al. [5] reported that the increased protein 
breakdown seen in mdx muscle was attributable to a non- 
lysosomal Ca2+-activated proteolytic process. Recent data, 
however, demonstrated that both cathepsins and calpains 
(i.e. the Ca2+-activated proteinases) do not contribute signifi- 
cantly to the overall muscle protein breakdown [I1 15], and 
do not play an important role in the breakdown of actin and 
myosins [16 18]. By contrast, the ATP-ubiquitin-dependent 
proteolytic pathway which was previously believed to degrade 
short-lived and abnormal proteins [19,20] is responsible for 
the bulk of muscle protein breakdown [11 15,21 25] including 
the degradation of the long-lived contractile proteins [17,18]. 
Increased mRNA levels for critical components of the ubi- 
quitin-proteasome-dependent proteolytic pathway have been 
systematically observed in various animal models of muscle 
wasting, such as fasting [11,25], denervation atrophy [25], can- 
cer [13,21,22], acidosis [12], sepsis [14,18], simulated weight- 
lessness [15], burn injury [26], and glucocorticoid administra- 
tion [11,23]. We have also recently shown that similar 
adaptations prevailed in muscle biopsies from head trauma 
patients who exhibited negative nitrogen balance, increased 
whole body rate of protein breakdown, and enhanced urinary 
3-methylhistidine excretion [24]. A concomitant s imulation of 
the ubiquitin-proteasome pathway with either the Ca2+-de - 
pendent [13] or the lysosomal process [11,22] or both 
[14,15,17,24] seems to prevail in some of these catabolic states. 
To our knowledge, the role of the ATP-ubiquitin-dependent 
proteolytic process has not been studied in muscular dystro- 
phies, although an accumulation f ubiquitylated proteins was 
observed in muscle biopsies from patients with oculopharyn- 
geal muscular dystrophy [27]. The present experiments were 
undertaken to determine (i) whether the ATP-ubiquitin-de- 
pendent proteolysis is activated in muscular dystrophy, and 
(ii) whether a coordinate activation of the lysosomal and 
Ca2+-activated proteinases prevails in such conditions. To ad- 
dress this question we measured mRNA levels for cathepsins 
D and L, m-calpain, ubiquitin, 14-kDa ubiquitin conjugating 
enzyme E2 (14-kDa E2), and subunits of the 20S proteasome 
in muscles from mdx mice and in muscle biopsies obtained 
from control and dystrophin-deficient pa ients. 
2. Materials and methods 
*Corresponding author. Fax: (33) 04 73 62 47 55. 
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2.1. Animals 
Mice of the mdx strain were kindly provided by Dr. J.-L. Gu6net 
(Institut Pasteur, Paris, France). They were compared to C57BL/6 
control mice obtained from lffa Credo (L'Arbresle, France). The 
mice were maintained in a temperature-controlled room (22+_I°C) 
on a 12-h light-dark cycle. They were fed ad libitum with a standard 
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diet (R03; UAR, Epinay sur Orge, France) and had free access to 
water. 
2.2. Rates of protein turnover 
Animals were killed by cervical dislocation at 5 weeks of age. Ex- 
tensor digitorum longus muscles were carefully dissected and incu- 
bated at approximately resting length by pinning their tendons on 
plastic supports. All tissues were incubated at 37°C in Krebs-Henseleit 
buffer (NaC1 120 raM, KC1 4.8 mM, NaHCO:~ 25 raM, CaC12 2.5 
mM, KH2PO4 1.2 mM and MgSO4 1.2 mM, pH 7.4) equilibrated 
with 95% 02 and 5% CO2, and containing 5 mM glucose, 0.1 U/ml 
insulin, 0.17 mM leucine, 0.10 mM isoleucine, and 0.20 mM valine to 
improve protein balance [28]. After 1 h of preincubation, muscles were 
transferred to a fresh medium of identical composition and further 
incubated for 2 h. 
The rate of protein synthesis was determined by incubating muscles 
in a medium containing 0.5 mM [U-llC]phenylalanine (Amersham 
Corp., Amersham, UK; specific radioactivity in the medium 500 
dpm/nmol), as previously described [13]. Tissues were homogenized 
in 10% trichloroacetic acid (TCA) and hydrolyzed in 1 N NaOH at 
37°C. Tissue protein mass was determined using the bicinchoninic 
acid procedure [29]. Rates of phenylalanine incorporation were con- 
verted into tyrosine equivalents as described [28], and expressed in 
nmol tyrosine incorporated/rag protein/h. 
Rates of protein breakdown were measured by following the rates 
of tyrosine release into the medium. Since muscle neither synthesizes 
nor degrades this amino acid, tyrosine release reflects the net break- 
down of proteins. Thus, rates of total protein degradation were cal- 
culated by adding the rate of protein synthesis and the net rate of 
tyrosine release into the medium [28]. Tyrosine was assayed by the 
fluorometric method of Waalkes and Udenfriend [30]. 
2.3. Human muscle biopsies 
Muscle biopsies were performed uring orthopedic surgery, in the 
Department of Pediatric Surgery of the H6tel Dieu Hospital in Cler- 
mont-Ferrand. The protocols were approved by an Ethical Committee 
(Consultative Committee for the Protection of Persons Undergoing 
Biomedical Research, R6gion d'Auvergne). 
The characteristics of the patients and of the muscles ampled are 
given in Table 1. Five DMD patients presenting a lack of dystrophin 
and six control subjects were studied. The latter were not suffering 
from any neuromuscular pathology, and presented no abnormality in
terms of muscle structure or fiber distribution. The age of the DMD 
patients tudied ranged between 7 and 21 years. All DMD patients 
were wheelchair bound, except he youngest one. 
2.4. Northern blot analysis 
Tibialis anterior muscles from control and mdx mice and human 
muscle biopsies were rapidly excised, frozen in liquid nitrogen and 
stored at 80°C. Total RNA was extracted as described by Chomc- 
zynski and Sacchi [31]. 20 ~tg of total RNA was electrophoresed in 1% 
agarose gel containing formaldehyde. RNA was electrophoretically 
transferred to a nylon membrane (GeneScreen, NEN Research Prod- 
ucts, Boston, MA, USA) and covalently bound to the membrane 
following UV crosslinking. The membranes were hybridized with 
cDNA probes encoding chicken polyubiquitin [32], rat 14-kDa E2 
[33], the rat [34] or human [35] C2 proteasome subunit, human ca- 
thepsin D [36], and human m-calpain [37]. The hybridizations were 
performed at 65°C with [a2P]cDNA fragments labelled by random 
priming. Following washes at the same temperature, the membranes 
were autoradiographed for 3 96 h at -80°C with intensifying screens 
on Hyperfilm-MP (Amersham International, Little Chalfont, UK). 
cDNA inserts encoding murine cathepsin L [38] and human m-calpain 
[37] were sub-cloned into Pstl sites of pGem-blue (Promega, Madison, 
WI, USA) and EcoRI-SmaI sites of pBluescript il KS + (Stratagene), 
respectively. The plasmids were linearized by HindIII (m-calpain) and 
PvuII (cathepsin L), and [:~2p]cRNAs were synthesized using T7 RNA 
polymerase. Hybridizations with m-calpain and cathepsin L 
[:~2P]cRNAs were performed as previously described [15]. After strip- 
ping of the different probes, the filters were reprobed with a mouse 
18S ribosomal probe (No. 63178, American Type Culture Collection, 
Rockville, MD, USA). Autoradiographic signals were quantified by 
digital image processing and analysis (NIH Image 1.54) and normal- 
ized using the corresponding 18S rRNA signals to correct for uneven 
unloading. 
2.5. Statistical analysis 
All data are expressed as means _+ S.E.M. The unpaired Student's t-
test was used for statistical analyses. Significance was defined at the 
0.05 level. 
3. Results and discussion 
Recent lines of evidence strongly suggest hat the ATP-ubi-  
quit in-dependent proteolytic pathway plays a major role in 
skeletal muscle. First, in several instances of muscle atrophy, 
there is no evidence for an activation of either the lysosomal 
[13,21] or the Ca2+-dependent [11,22] proteolytic process. Sec- 
ondly, cathepsins and calpains only account for a minor part 
of overall protein breakdown in muscles from both control 
and cachectic animals where protein breakdown rises [11-15]. 
Thirdly, both lysosomal and Ca2+-activated proteinases do 
not degrade myofibril lar proteins [16 18]. By contrast, in 
any catabolic state so far studied in rodents [11- 
15,18,21,22,26], it has been reported that the bulk of increased 
protein breakdown is due to the activation of a non-lysosomal 
and Ca2+-independent process. This process is ATP-depend- 
ent [11 13,18,22,26], and increased expression of ubiquit in 
[11 15,18,21 26], 14-kDa E2 involved in the ubiquitylation 
of protein substrates [13-15,23,24,33], and subunits of the 
20S proteasome [12-15~22 5], which is the proteolytic core 
of the 26S proteasome that degrades ubiquitin conjugates, 
systematically paralleled the changes in protein breakdown 
measured in incubated muscles. Furthermore,  since the break- 
Table 1 
Characteristics of dystrophin-deficient a d control patients 
Age (years) Sex Muscle Diagnosis Dystrophin Fiber necrosis and 
fibrosis 
7 M deltoid DMD - + 
l0 M triceps surae DMD - ++ 
12 M hip adductor DMD - +++ 
14 M tensor fasciae latae DMD +++ 
21 M deltoid DMD - +++ 
5 M deltoid psychosis + - 
8 F triceps surae tiptoes walker + - 
10 M piriformis sciatic compression + - 
10 M hip adductor cerebral palsy + 
11 M hip adductor femoral anteversion + 
15 M paravertebral kyphosis + - 
M: male; F: female. The degree of fiber necrosis and fibrosis was evaluated by histoenzymatic analysis and classified as 
intermediate (++) or severe (+++). All DMD patients were dystrophin (-).  Control subjects were dystrophin (+) and 
( ). 
absent (-) ,  moderate (+), 
fiber necrosis and fibrosis 
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Fig. 1. Quantification of mRNA levels for components of the ubi- 
quitin-proteasome proteolytic pathway in skeletal muscle from mdx 
mice (A) and DMD patients (B). Open bars, control muscles: black 
bars, dystrophic muscles. RNA was extracted, electrophoresed, 
transferred to a nylon membrane and hybridized with a'2p-labeled 
cDNAs encoding ubiquitin, 14-kDa E2, and rat (RC2) or human 
(HC2) C2 proteasome subunit, as described in Section 2. Alter 
stripping of the probes, blots were rehybridized with an 18S riboso- 
mal oligonucleotide. Autoradiographic signals are expressed as a 
percentage of controls corrected for 18S rRNA abundance, to take 
into account slight variations in RNA loading. Data are means 
+ S.E.M. for n=6 mice and 5 6 patients. Representative Northern 
blots are also shown. 
down of actin and myosin requires ATP [17,18], and because 
ubiquitylated proteins were found in the myofibrillar fraction 
[39], it has been suggested that the ubiquitin-proteasome pro- 
teolytic process is critical for the breakdown of the major 
contractile proteins. 
In the present experiments we attempted to determine 
whether increased mRNA levels for components of the 
ATP-ubiquitin-dependent proteolytic pathway prevailed in 
dystrophin-deficient muscles, mdx animals were studied at 5 
weeks of age, i.e. at a stage of development when total protein 
breakdown was elevated compared to control animals (Table 
2), as described [4]. Since protein synthesis was also previously 
reported to be increased in mdx muscles [5], we verified that 
the net protein breakdown was also enhanced in such condi- 
tions (Table 2). However, in striking contrast with all various 
muscle wasting conditions so far studied in rodents where 
protein breakdown was elevated [11 15,21 23,25,26], we 
found no significant variation in mRNA levels for compo- 
nents of the ubiquitin-proteasome proteolytic pathway in 
muscle from mdx mice (Fig. 1A). Interestingly, the lack of 
change in mRNA levels for ubiquitin in mdx muscle did not 
result from a total blockade in the responsiveness of the ubi- 
quitin genes due to the dystrophic state. Indeed, recent evi- 
dence has been provided that ubiquitin expression was in- 
creased to the same extent in normal and mdx muscle fibers 
after exercise [40]. mRNA levels for ubiquitin, 14-kDa E2 and 
proteasome subunits also increased in muscle biopsies from 
head trauma patients who exhibited rapid muscle wasting [24]. 
However, again, no similar changes prevailed in muscle biop- 
sies from DMD patients (Fig. 1B). Ubiquitin-proteasome-de- 
pendent proteolysis is now recognized to be of major impor- 
tance for the breakdown of contractile proteins [17,18]. Thus, 
the lack of detectable activation of this pathway in dystro- 
phin-deficient muscles is presumably due to the very progres- 
sive changes in muscle mass in such conditions. For example, 
in many instances of induced cachexia in rodents, the loss of 
muscle proteins is ~-, 5%/day [14,15,22]. In the present experi- 
ments, the difference in muscle mass between 5 weeks old 
dystrophic and control mice is at most 0.7%/day in the tibialis 
anterior muscle and 0.5%/day in the extensor digitorum 
longus muscle (Table 2). Furthermore, these differences do 
not entirely reflect muscle wasting, but impaired growth. Al- 
ternatively, some regulatory mechanisms may prevent sus- 
tained increased expression of proteolytic genes in muscular 
dystrophy, to avoid excessive and rapid muscle wasting. Fi- 
nally, it was recently reported that increased mRNA levels for 
proteasome subunits in atrophying muscles either reflected 
increased transcription [41] or entered active translation [15]. 
However, we cannot rule out a possible activation of the 
ubiquitin-proteasome proteolytic pathway based on the lack 
of variation of mRNA levels for components of this pathway. 
The mechanism by which elevated protein breakdown re- 
sults in muscle wasting in mdx mice is assumed to be Ca 2+- 
dependent, based on indirect evidence. First, elevated intracel- 
lular Ca 2+ concentration resulted in increased rates of proteo- 
lysis in muscles from 5 weeks old mdx mice [4], Secondly, the 
!32-agonist clenbuterol, which increases the activity of the cal- 
pain inhibitor calpastatin, can retard muscle wasting in mdx 
mice [42]. The enhanced mRNA levels for m-calpain observed 
here (Fig. 2A) provided strong direct evidence for a role of 
Ca2+-dependent proteinases in muscle wasting in mdx mice. 
Table 2 
Muscle/body weight ratios and protein turnover in the extensor digitorum longus (EDL) of control and mdx mice 
Muscle mass/body weight ratio Protein synthesis Total protein Net protein 
breakdown breakdown 
tibialis anterior EDL 
Control mice 1.551 +- 0.049 0.469 _+ 0.009 0.211 + 0.007 0.842 _+ 0.072 0.629 _+ 0.073 
mdx mice 1.165 -+ 0.169* 0.378 _+ 0.022** 0.427 +- 0.057"* 1.558 +_ 0.184** 1.130 -+ 0.178* 
Difference -0.386 -0.091 +0.216 +0.716 +0.501 
Values are means-+ S.E.M. for six animals. Protein turnover data are expressed in nmol tyrosine/mg protein/h (for more details see Section 2). 
*P<0.05, **P< 0.005 vs. controls. 
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However, in human muscle biopsies, we observed no signifi- 
cant variation in mRNA levels for m-calpain (Fig. 2B) in 
accordance with recent observations by Sakamoto et al. [43]. 
The precise significance of changes in mRNA levels for Ca 2+- 
activated proteinases in different muscle wasting conditions is 
still unclear. Enhanced expression of m-calpain was associated 
with increased enzyme activity in the atrophying unweighted 
soleus muscle [15], suggesting a transcriptional regulation. By 
contrast, no change in B- and m-calpain activity occurred in 
the muscles of fasted rabbits, although the mRNA levels for 
It- and m-calpain were elevated [44]. Furthermore, a third 
calpain, p94, that is expressed abundantly only in skeletal 
muscle, has been characterized [45]. Mutations in p94 cause 
limb-girdle muscular dystrophy type 2A [46]. There is some 
evidence that p94 was expressed in proportion of dystrophin, 
whose absence causes DMD [43]. Interestingly, the expression 
of p94 was also down-regulated in the atrophying muscles 
from interleukin-6 transgenic mice [47]. Thus, muscle atrophy 
seems to be associated with decreased p94 mRNA levels. 
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Fig. 2. Quantification of mRNA levels for m-calpain in skeletal 
muscle from mdx mice (A) and DMD patients (B). Open bars, con- 
trol muscles; black bars, dystrophic muscles. RNA was extracted, 
electrophoresed, transferred to a nylon membrane and hybridized 
with a 32p-labeled riboprobe (A) or cDNA (B) encoding m-calpain, 
as described in Section 2. After stripping of the probe, blots were 
rehybridized with an 18S ribosomal oligonucleotide. Autoradio- 
graphic signals are expressed as a percentage of controls corrected 
for 18S rRNA abundance, to take into account slight variations in 
RNA loading. Data are means + S.E.M. for n = 6 mice and 5-6 pa- 
tients. Representative Northern blots are also shown. 
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Fig. 3. Quantification of mRNA levels for cathepsins D and L in 
skeletal muscle from mdx mice. Open bars, control muscles; black 
bars, dystrophic muscles. RNA was extracted, electrophoresed, 
transferred to a nylon membrane and hybridized with a 32p-labeled 
cDNA (cathepsin D) or a 32p-labeled riboprobe (cathepsin L), as 
described in Section 2. After stripping of the probes, blots were re- 
hybridized with an 18S ribosomal oligonucleotide. Autoradiographic 
signals are expressed as a percentage of controls corrected for 18S 
rRNA abundance, to take into account slight variations in RNA 
loading. Data are means_+S.E.M, for n=6 mice. Representative 
Northern blots are also shown. 
Finally, MacLennan et al. [5] demonstrated that enhanced 
muscle proteolysis in mdx muscle was attenuated by inhibitors 
of thiol proteases (e.g. leupeptin and E-64 which inhibit both 
the calpains and cathepsins B, H, and L), but not by the weak 
base methylamine, which only affects lysosomal protein 
breakdown. The lack of significant variations in mRNA levels 
for both cathepsins D and L in mdx muscle supported these 
observations (Fig. 3). Alternatively, these data may suggest 
that the possible involvement of cathepsins in elevated protein 
breakdown during muscular dystrophy [(~8] did not reflect a 
transcriptional regulation. 
In conclusion, we have shown that in contrast with all other 
muscle wasting conditions o far studied, there is no detect- 
able activation of the ubiquitin-proteasome proteolytic path- 
way in dystrophic muscle from mdx mice and DMD patients. 
We suggest that the lack of change in mRNA levels for critical 
components of this pathway resulted from the very progres- 
sive changes in muscle mass that characterize muscular dys- 
trophies. Alternatively, some mechanisms may prevent sus- 
tained increased expression of proteolytic genes in muscular 
dystrophy, to avoid excessive and rapid muscle wasting. In 
contrast, the increased mRNA levels for m-calpain in mdx 
muscle strongly support a selective activation of the Ca 2~- 
dependent proteinases. These proteinases may selectively de- 
grade soluble or membrane proteins. For example, they could 
be responsible for the dramatic loss of all the components of 
the dystrophin-glycoprotein complex which is characteristic of
dystrophin deficiency [48]. 
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